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Abstract
Induction of local antiviral immune responses at the mucosal portal surfaces where HIV-1 and other viral pathogens are
usually first encountered remains a primary goal for most vaccines against mucosally acquired viral infections. Exploring
mucosal immunization regimes in order to find optimal vector combinations and also appropriate mucosal adjuvants in the
HIV vaccine development is decisive. In this study we analyzed the interaction of DNA-IL-12 and cholera toxin B subunit
(CTB) after their mucosal administration in DNA prime/MVA boost intranasal regimes, defining the cooperation of both
adjuvants to enhance immune responses against the HIV-1 Env antigen. Our results demonstrated that nasal mucosal DNA/
MVA immunization schemes can be effectively improved by the co-delivery of DNA-IL-12 plus CTB inducing elevated HIV-
specific CD8 responses in spleen and more importantly in genital tract and genito-rectal draining lymph nodes. Remarkably,
these CTL responses were of superior quality showing higher avidity, polyfunctionality and a broader cytokine profile. After
IL-12+CTB co-delivery, the cellular responses induced showed an enhanced breadth recognizing with higher efficiency Env
peptides from different subtypes. Even more, an in vivo CTL cytolytic assay demonstrated the higher specific CD8 T-cell
performance after the IL-12+CTB immunization showing in an indirect manner its potential protective capacity.
Improvements observed were maintained during the memory phase where we found higher proportions of specific central
memory and T memory stem-like cells T-cell subpopulations. Together, our data show that DNA-IL-12 plus CTB can be
effectively employed acting as mucosal adjuvants during DNA prime/MVA boost intranasal vaccinations, enhancing
magnitude and quality of HIV-specific systemic and mucosal immune responses.
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Introduction
Natural transmission of HIV and SIV occurs predominantly via
mucosal surfaces, which are the major entry points of these viruses
and concomitantly are the first line of host defense to combat the
infection. Once the mucosal epithelial barrier is crossed, a small
founder population of infected cells is rapidly established. Then,
local viral expansion occurs during the first week and later, a self-
propagating systemic infection throughout the secondary lym-
phoid organs is established [1,2]. Thus, the small infected founder
populations implied during HIV-1 mucosal transmission clearly
indicate that the greatest opportunities for prevention may be
strategies that target these initially small and genetically homoge-
neous foci of mucosal infection in the first week of infection [2].
However, despite evidences related to the kinetic characteristics of
the infection and the mucosal natural transmission of the virus,
mucosal surfaces are not targeted by most HIV vaccines currently
under trial (http://www.iavi.org). Conversely, most of the research
emphasis is focused on the analysis of systemic routes of
inoculation, mainly the intramuscular one.
The stimulation of the mucosal immune response can be
achieved by the administration of immunogens at mucosal
inductive sites, where specialized organized lymphoepithelial
follicular structures exist. The concept of a common mucosa-
associated system regulating and coordinating immune response at
mucosal surfaces implied an important advance in our under-
standing of protection against mucosal pathogens. This system,
called the mucosa-associated lymphoid tissue, is based on primed
T and B lymphocytes that migrate from the site of antigen
presentation via the lymphatic and blood to selectively home to
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lymphoid tissue at distant sites in gastrointestinal, respiratory,
genitourinary, and other mucosa-associated regions [3]. Various
studies have demonstrated that both oral and intranasal admin-
istration of antigens are capable of inducing immune responses at
distant effector sites [4]. In this sense, the use of the intranasal
route to stimulate inductive sites in the respiratory tract has been
of considerable interest over the past years, demonstrating to be a
feasible mucosal route to effectively induce both systemic and
mucosal immune responses at distal places after mice [5], monkeys
[6,7] as well as humans immunization [8].
Evidences from experimental data and from natural HIV
infection suggest that in order to control both entry and systemic
dissemination, an effective HIV vaccine may need to stimulate
both arms of the adaptive immune system, eliciting cellular and
humoral immunity systemically as well as at mucosal surfaces.
The application of DNA/MVA vaccine vectors expressing HIV
antigens by mucosal routes have been previously explored in
macaques [9] and diverse mice models [10]. In a previous study,
we were able to demonstrate that a MVA vector expressing HIV
gp160 intranasally delivered after MVAenv/MVAenv and
DNAenv/MVAenv schemes, plus the experimental mucosal
adjuvant cholera toxin (CT), induced mucosal CD8 T- cell
responses and also local antibodies in the genital tract and genito-
rectal draining lymph nodes [5]. Although CT is the mucosal
adjuvant most employed for research experiments, its application
is not possible in human trials due to its toxicity. Thus, the
identification and characterization of adjuvant-molecules is very
important for mucosal immunization approaches in order to
induce long lasting protective immunity. On the other hand, to the
extent in which vaccines need to be focused not only on creating
an immune response against an antigen, but also on the quality of
that response, the role of adjuvants is becoming increasingly
significant. Even more, over the past years several evidences
indicated that the main characteristic that is really relevant in anti-
viral T-cell immunity is its quality in terms of the type of cytokines
secreted, cytotoxic activity, proliferative capacity, etc [11]. Benefits
of the inclusion of DNA-IL-12 in DNA/viral vector schemes by
parenteral routes have been largely explored, specially demon-
strating its potency to increment cellular immune responses
[12,13] and also its enhancement control against a pathogenic
SIV challenge in the macaque model [14]. Interestingly, with
respect to intranasal IL-12 application different reports demon-
strated its effectiveness to modulate antigen-specific immune
response and to enhance immunization strategies for mucosal
vaccines [15,16]. In a previous reported study it was shown that in
an intranasal vaccination using IL-12 plus CTB as adjuvants, both
molecules can act in synergy to enhance mucosal and systemic
antibodies against HIV-1 glycoproteins [17].
Considering the importance of exploring mucosal immunization
regimes in order to find optimal vector combinations and also
appropriate mucosal adjuvants in the HIV vaccine development,
we conducted the present study in which we analyzed the
interaction of DNA-IL-12 and CTB after their mucosal admin-
istration in DNA prime/MVA boost intranasal regimes. The
novelty of our study reside in that we found a cooperation for IL-
12+CTB to improve specific systemic and mucosal cellular
immune responses against HIV antigens after DNA/MVA
mucosal delivery. We have carried out an exhausted character-
ization of the specific immune response generated against HIV-1
gp160 antigen as a model. Induced T-cell response was
characterized in terms of magnitude, pattern of cytokines secreted,
amplitude (cross-reactivity against different HIV Env peptide
subtypes), and most importantly in terms of the in vivo cytotoxicity
capacity. Remarkably, these evaluations were performed at both
systemic and mucosal genital tract compartments.
Materials and Methods
Cell lines
BHK-21 cells (fibroblast adherent cell-line derived from
hamster kidney, ATCC Cat No CCL-10) were maintained at
37uC in a 5% CO2 atmosphere in Dulbecco’s Modified Eagle’s
Medium (DMEM, Gibco BRL, USA) supplemented with 2 mM
L-glutamine (Gibco BRL), 100 U/ml penicillin (Gibco BRL) and
0.1 mg/ml streptomycin (Gibco BRL) and 10% fetal bovine serum
(FBS, Natocor) (DMEM 10%).
DNA vectors
DNA plasmid (pCR3) expressing gp-120 modified for optimized
codon usage (syngp120 mn V3 LAI) from HIV-1 strain IIIB
(DNA-EnvB) as previously described [18] was a generous gift of
Ju¨rgen Haas (Munich, Germany). The DNA plasmid carrying the
sequence coding for IL-12 (expressing murine IL-12, p35 and p40
genes DNA-IL-12) [12,19] was kindly provided by Dr. Mariano
Esteban (Madrid, Spain). To corroborate the expression of the
cytokine from the DNA-IL-12 plasmid an assay to quantify the
amount of cytokine released into the supernatant of transfected
cells was conducted. For this, 293-T cells (human epithelial cells)
and 3T3 cells from mouse origin (mouse fibroblasts) were
transfected with 5 mg of DNA-IL-12, using Lipofectamine
(Invitrogen, USA), following the manufacturer’s instructions.
The amount of cytokine was quantified in the supernatant by
ELISA, 48 h post-transfection (optEIA, BD). Transfected cells
produced 2286104 pg/ml (293-Tcells) and 1786103 pg/ml (3T3
cells) of IL-12 in average (versus 700 (293-Tcells) and 1400 (3T3
cells) pg/ml background levels of DNA-empty transfected cells)
thus verifying the ability of the vector to express this molecule
(data not shown). Plasmids were purified with Endo free Maxi-
Prep purification kits (NucleoBond Xtra Maxi Plus EF, Macherey-
Nalgen, Germany) using pyrogen-free material and eluted in TE
buffer.
Viruses
MVA recombinant virus encoding the complete IIIB HIV-1 gp-
160 (MVA-EnvB) used in this study was previously described
[20,21] and kindly provided by Dr. Mariano Esteban (Madrid,
Spain). Amplified viral stocks were grown in BHK-21 cells. Viruses
were released from the infected cells by sonication, then purified
by ultracentrifugation through 45% sucrose-cushion as elsewhere
indicated [22]. MVA-EnvB was titrated by immunostaining of
fixed BHK-21 infected cell-cultures with polyclonal serum reactive
against VV proteins.
Mice, immunization protocols, sample collection and
processing
Specific pathogen-free (SPF) female BALB/c mice (H-2d) six to
eight weeks-old were purchased from the Laboratories of the
School of Veterinary Sciences, University of La Plata, Buenos
Aires, and then housed in our animal facilities. All experiments
were carried out in strict accordance with the recommendations in
the Guide for the Care and Use of Laboratory Animals of the
National Institutes of Health. The protocol was approved by the
Committee of Care and Use of laboratory animals from the School
of Medicine, University of Buenos Aires (Permit Number: 508/
2009).
The DNA-EnvB (50 mg) prime/MVA-EnvB (107 PFU) boost
intranasal immunization scheme was applied in anesthetized mice
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spaced by 14 days. Both vaccine vectors were diluted in sterile
PBS, in 20 ml of final volume. Doses and combination of adjuvants
applied in the different immunization schemes are depicted in
Table 1. DNA-IL-12 was administered during the priming doses
at the indicated dose (50 or 100 mg). Cholera toxin B subunit
(CTB, Sigma-Aldrich) and complete cholera toxin (CT, Sigma-
Aldrich) were resuspended in sterile distilled water and then
diluted in PBS in order to give 10 mg doses. Ten, 30 or 53 days
after the last immunization, mice were sacrificed to collect
samples. The number of animals of each experimental group
was of 4 or 6 animals depending of the experiment.
Blood samples were obtained by cardiac punction from
anesthetized mice. Blood was allowed to clot 4 hours at room
temperature. After leaving samples at 4uC overnight, they were
spun down in a microcentrifuge, and sera were removed and
stored at 280uC. Vaginal washings were obtained by flushing ten
times with 50 ml of PBS into the vaginal canals and it was repeated
two times; then samples were spun down to remove cellular debris
and frozen at 280uC. Splenocytes and lymphocytes from the
genito-rectal associated lymphoid tissue (iliac lymph nodes, ILNs),
and nasal-associated lymphoid tissue (cervical lymph nodes; CLNs)
were isolated by routine methods. Lymphocytes from urogenital
tract were obtained as previously described [5,23]. Briefly, the
urogenital tracts (vagina, cervix, and uterine horns) were
aseptically removed, and tissue was longitudinally spliced, cut in
very small pieces, and washed with RPMI (RPMI-1640 medium,
Gibco BRL) plus 5% FBS. Tissues segments were dissociated
enzymatically with a mixture of collagenase type VIII (Sigma-
Aldrich) and dispase I (Roche Diagnostics, Germany) in RPMI 5%
FBS, with agitation for 30 min at 37uC. After three digestion
cycles, lymphocytes were enriched by placing the cell suspension
on a discontinuous gradient containing 75% and 40% Percoll
(Amersham Pharmacia Biotech, Bucks, U.K.). After centrifugation
(1700 rpm, 20 min) the interface layer was harvested, washed, and
finally resuspended in RPMIc (RPMI-1640 medium, Gibco BRL,)
supplemented with 2 mM L-glutamine (Gibco BRL), 100 U/ml
penicillin (Gibco BRL), 0,1 mg/ml streptomycin (Gibco BRL),
10 mM HEPES (Gibco BRL) and b-Mercaptoethanol, with 10%
fetal bovine serum (Natocor).
Peptides
The previously characterized gp160 V3 MHC class I-restricted
p18IIIB-I10 RGPGRAFVTI peptide [24,25] was employed.
Potential T-cell epitopes (PTE) peptides of Env protein were
obtained from the NIH AIDS Reagent Program. The PTE
peptides set represent the most frequent sequences of circulating
HIV-1 strains worldwide. The peptides are 15 aa in length. The
global PTE peptides cover all PTEs with a frequency equal to or
greater than 15% in any one of the subtypes A, B, C and non-
ABC. Here, the PTE peptides were pooled in five pools
representing the whole protein: Gp1201 (aa 1 to 154), Gp1202
(aa 155 to 284), Gp1203 (aa 285 to 511.), Gp411 (aa 512 to 689.)
and Gp412 (aa 690 to 842). In all cases, lyophilized peptides were
dissolved in dimethyl sulfoxide (DMSO, Sigma-Aldrich) and
stored at 220uC. V3 and peptides pools were used in assays to
stimulate T-cells at 2 mg/ml, or at the indicated concentration.
ELISPOT assays
ELISPOT assays were performed with freshly isolated lympho-
cytes cultured in RPMIc as described previously [25]. Briefly,
0,1256106 to 106 cells were plated on duplicate or triplicate wells
in 96-wells ELISPOT plates (MultiScreen IP plates, Millipore,
USA) previously coated with anti-mouse IFN-c Ab (BD ELISPOT
mouse IFN-c ELISPOT pair) or anti-mouse IL-2 Ab (BD
ELISPOT mouse IL-2 ELISPOT pair) The cells were stimulated
with individual or pooled peptides. Negative controls were
incubated with RPMIc plus 0.04% or 0.08% of DMSO, and cells
treated with ConA (1 mg/ml) were included as positive control.
Plates were incubated for 24 h at 37uC in a 5% CO2
atmosphere, later washed twice with destilated water and three
times with PBS plus 0,05% Tween-20 (PBS-T) and incubated
during 16–18 h at 4uC with the corresponding detecting Ab
solution (BD ELISPOT mouse IFN-c/IL-2 ELISPOT pair).
Thereafter, plates were washed and incubated during 1 h with
Streptavidin-Horseradish Peroxidase (HRP) (BD). Wells were
washed and spots were developed by adding 1 mg/ml solution of
the substrate 3,39-diaminobenzidine tetrahydrochloride (Sigma-
Aldrich) containing 0.03% hydrogen peroxide. Plates were
scanned on an ImmunoSpot reader (Cellular Technology Ltd.)
and specific spots were counted using the ImmunoSpot software.
Functional avidity referred as to the activation threshold in
response to defined concentrations of exogenous peptide was
performed following the protocols previously described [26].
Briefly, limiting peptide dilutions (from 20 mg/ml to
0.00002 mg/ml) were performed and then the sensitizing dose of
peptide concentration required to induce a half-maximum IFN-c
secreting cells (SD50) in ex vivo assays was determined with a
sigmoid dose-response curve (GraphPad software). In these Elispot
assays the maximal counts for each group were evaluated with
comparable E:T ratios for each group. To do this, the number of
effector cells/well that was put for each group was selected taking
into account the number of spleen cells sufficient to give a response
of approximately 200 spots/well.
Table 1. Intranasal immunization schemes administered.
Groups a Prime: Day 0 Boost: Day 14
None adjuvant DNA-EnvB MVA-EnvB
CT DNA-EnvB + CT (10 mg) MVA-EnvB + CT (10 mg)
IL-1250 DNA-EnvB + DNA IL-12 (50 mg) MVA-EnvB
IL-12100 DNA-EnvB + DNA IL-12 (100 mg) MVA-EnvB
IL-1250+CTB DNA-EnvB + DNA IL-12 (50 mg) + CTB (10 mg) MVA-EnvB + CTB (10 mg)
IL-12100+CTB DNA-EnvB + DNA IL-12(100 mg)+ CTB (10 mg) MVA-EnvB + CTB (10 mg)
CTB DNA-EnvB + CTB (10 mg) MVA-EnvB + CTB (10 mg)
aAll groups were immunized with a DNA/MVA immunization scheme by the intranasal route. At day zero mice were primed with DNA-EnvB (50 mg) and 14 days later all
groups were boosted with MVA-EnvB (107 PFU/dose). Time as well as quality and quantity of the adjuvants co-inoculated are indicated.
doi:10.1371/journal.pone.0107524.t001
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Ab measurements by ELISA
ELISA assay was used to determine the presence of Abs against
gp160 in serum and vaginal washings following procedures
previously described [21]. Purified gp120LAV (Protein Sciences
Corp) was employed to coat the 96-well plates at 1 mg/ml. Ab
detection was performed after the addition of Biotin-conjugated
goat anti-mouse IgG, IgG1, IgG2a or IgA (Invitrogen) followed by
the addition of Streptavidin-Horseradish Peroxidase (HRP) (BD).
Reaction was developed with the peroxidase substrate TMB
(Sigma) and stopped by adding 2 N H2SO4, absorbance was
measured at 450 nm on a Multiskan Plus plate reader (Labsys-
tems, Chicago, Ill).
T cell-specific cytokine production
Cells were suspended in RPMIc 10% FBS and cultured in
triplicate wells (106 cells/well) into 96-well round-bottom plates
and stimulated with the V3 peptide (2 mg/ml) or with the
recombinant gp120 HIV-1 BaL (NIH AIDS Research and
Reference Reagent Program) at 1 mg/ml. Cells stimulated with
ConA (1 mg/ml), or medium with the appropriate % of DMSO
were the positive and negative controls respectively. After 72 h
incubation at 37uC in 5% CO2, culture supernatants were stored
at 280uC and cytokine analysis was performed using the mouse
Th1/Th2 cytokine kit (CBA, Cytometric Bead Array, BD),
according to the manufacturer’s instructions. The threshold values
to consider a positive response was that cytokine-quantities had to
be superior to the average values found in negative control wells of
each group plus 3SD.
Simultaneous intracellular cytokine staining (ICS) and
cytotoxic activity assessment
Cells (106cells/wells) were stimulated with the V3 peptide at a
final concentration of 2 mg/ml during 5 h in 96-well U bottom
plates at 37uC in 5% CO2 in the presence of the costimulatory
antibody anti-CD28 (1 ng/ml; BD Pharmingen), brefeldin A
(1 ml/ml BD, GolgiPlug). Monensin (0.7 ml/ml; BD, GolgiStop)
and the monoclonal Abs (mAb) anti-CD107a and anti-CD107b
both labeled with FITC (CD107a/b-FITC; BD Pharmingen) were
added in some experiments, these molecules are degranulation
markers that allow the detection of cytotoxic activity of CD8 T-
cells [27]. Negative and positive controls consisted of cells
stimulated with RPMIc plus 0.08% DMSO, or PMA ionomycin
(10 ng/ml phorbol myristate acetate (PMA) plus 250 ng/ml
ionomycin (Sigma-Aldrich)) respectively. Afterwards, cells were
washed and stained with surface antibodies: CD3-APC and CD8-
PerCP (BD Pharmingen), living cells were identified after staining
with near-IR-fluorescent reactive dye (LIVE/DEAD, Invitrogen).
Cells were incubated for 30 min at 4uC, and then permeabilized
and fixed using the fixation/permeabilization kit (BD, Cytofix/
Cytoperm). After the permeabilization/fixation step, cells were
stained using anti-IFN-c-PE, TNF-a-PE-Cy7 and IL-2-FITC if
applicable (BD, Pharmingen) for 30 min at 4uC in obscurity. After
two washes cells were stored at 4uC until being acquired in a BD
FACSCanto flow cytometer.
Data acquisition and analysis were done with the BD
FACSDiva software. Instrument settings and fluorescence com-
pensation were performed on each testing day using unstained and
single stained samples. Stimulated cells stained for surface
molecules and isotype matched controls were included in each
experiment.
Proliferation assay
Proliferation assay was performed as previously described [28].
Briefly, splenocytes were resuspended (406106 cells/ml) in PBS
plus 1% FBS and labeled with 1.25 mM of carboxyfluorescein
succinimidyl ester (CFSE) (Invitrogen, USA) at 37uC for 8 min-
utes. The reaction was quenched with FBS and cells were washed
with RPMIc. Then, cells were resuspended in RPMIc at a density
of 56106/ml. Cells were cultured in 12 wells plates for 4 days at
37uC and 5% CO2 atmosphere with medium only or 2 mg/ml of
V3 peptide. Positive controls were stimulated with ConA. After
four days, lymphocytes were harvested, counted and washed with
RPMIc. Then, cells were stained for 30 minutes at 4uC with anti-
mouse CD3-APC, CD8-PerCP, CD44, and CD62L (in memory
experiments) (BD Pharmingen) plus viability dye near-IR-fluores-
cent reactive (LIVE/DEAD, Invitrogen). Cells were then washed
and acquired in a BD FACSCanto flow cytometer.
In vivo cytotoxicity
In vivo cytotoxicity assays were performed as previously
described with brief modifications [29,30]. Splenocytes from naı¨ve
mice were pooled and labeled at 406106 cells/ml with 1 mM
CFSE (CFSElow) or 8 mM CFSE (CFSEhigh) (Invitrogen) in PBS
plus 1% FBS at 37uC for 8 minutes in the dark and quenched with
an equal volume of 100% FBS at room temperature. After
washing with RPMIc 10% FCS, CFSEhigh cells were pulsed with
V3 peptide at a final concentration of 5 mg/ml during 30 minutes
at 37uC. After 3 washes, cells from each population were mixed
together and 206106 cells were injected i.v. in the different
immunized mice groups. Four and 16 h later, mice were sacrificed
and individual spleens were analyzed by flow cytometer. In vivo
cytolysis was calculated as (1 - (ratio naı¨ve/ratio immune))6100,
where the ratio = percentage CFSElow/CFSEhigh.
Data analysis
Statistical analyses to compare inter-group responses were
performed using GraphPad Prism 5 (Graph-Pad Software)
employing parametric (Student’s t-test; or one-way ANOVA with
post-Bonferroni correction), or non-parametric statistics (Mann-
Whitney test). For all tests, a p value minor to 0.05 was considered
statistically significant.
Results
Nasal co-administration of DNA-IL-12 plus CTB cooperate
to induce significant enhancement effects in systemic
and mucosal cellular immune responses against HIV-1
Env antigen during DNA/MVA immunization schemes
Previous studies have demonstrated the efficacy of the nasal
route of inoculation to induce mucosal immune response in
vaccination schemes in which MVA vectors were employed [10].
However, neither the analysis of the IL-12 mucosal adjuvant effect
applied during mucosal DNA/MVA immunizations nor its effects
after its combination with CTB with these vector-based immuni-
zations have been deeply analyzed so far.
Thus, with the aim to evaluate the IL-12 plus CTB action on
DNA/MVA regimes administered by intranasal route, different
immunization schemes were designed in order to delineate the best
DNA-IL-12 dose and to discern the benefits of IL-12 and CTB co-
delivery.
Table 1 depicts immunizations applied by intranasal route, in
which all mice groups received the same DNA-EnvB dose during
priming, but differed whether adjuvants were co-applied or not
(control group: without adjuvants). Two different DNA-IL-12
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doses were administered with or without CTB, whereas one group
received complete CT and the other one CTB only. Fourteen days
later, all groups were boosted with 107 PFU/animal of MVA-
EnvB, but in those groups which had previously received CT or
CTB during priming, the viral boost had the incorporation of CT
or CTB respectively. Ten days after the booster dose, the specific
cellular immune response generated by the different immunization
regimes was analyzed at systemic level (spleen) and also at mucosal
lymph nodes, like the CLNs (cervical lymph nodes, draining the
nasal mucosa) and the ILNs (iliac lymph nodes, draining the
genito-rectal mucosa).
Figure 1 shows data from a representative experiment, in which
specific cellular immune responses were evaluated as number of
anti-Env (anti-p18IIIB-I10 peptide) IFN-c secreting cells. In the
spleen (Figure 1A upper panel), when DNA-IL-12 was adminis-
tered alone with the antigen both DNA-IL-12 doses generated
similar responses, representing a two-fold enhancement with
respect to the magnitude of the response found in the control
group (but the enhancements recorded did not reach significant
differences). However, when CTB was co-inoculated with DNA-
IL-12 at priming and also during the MVA boost dose, significant
increases in the numbers of IFN-c secreting cells could be observed
in comparison to the control group and to the respective groups
without CTB (IL-1250+CTB vs control p,0.001, IL-1250 vs IL-
1250+CTB p,0,001, IL-12100+CTB vs control p,0.001 and IL-
12100 vs IL-12100+CTB p = 0,01). Surprisingly, the minor DNA-
IL-12 dose plus CTB (IL-1250+CTB) generated the highest
response representing a mean increment of seven-fold in the
magnitude of the response compared to that detected in the
control group (Figure 1B) (mean of 1257 vs 185 IFN-c SFU/106
cells). This result denoted that at least in the spleen, the IL-12
50 mg dose generated a effect co-operative enhancement with
CTB that seems to be synergic (mean increment of 7,5-fold). It
must be noted that to verify that unspecific plasmid stimulation
was not present in the immunization schemes performed along the
study, we did an extra immunization experiment in which two
mice groups were immunized as the control (non adjuvant) and
IL-1250 groups and a third group was included (DNA-empty)
which received during the priming dose DNA-EnvB (50 mg) +
DNAempty (50 mg) (Fig S1A). Ten days after immune response
induced at spleen was evaluated by Elispot (Fig S1B) and it can be
clearly seen that the magnitude of the response generated in the
control group (none adjuvant) that was employed along the
different experiments performed in the paper, was comparable to
that produced in the mice group i.n. primed with DNA-
EnvB(50 mg) +DNAempty (50 mg) (mean of 134 vs 129 IFN-c
SFU/106 cells). On the other hand a significant higher response
(p,0.01) was generated in the IL-1250 group in comparison to
either the non adjuvant or the DNA-empty group.
When responses at mucosal draining lymph nodes were studied,
both schemes in which DNA-IL-12 plus CTB were co-inoculated
during the priming dose, and CTB was also incorporated during
the MVA boost, generated the highest responses in CLNs (p,
0,001 vs the control group) and more importantly in ILNs (p,0,01
vs the control group). Then, we considered important to analyze
the percentage of experiments in which the application of
adjuvants generated a significant enhancement in the cellular
immune response (% Adjuvant efficacy (%AE)) and the mean of
fold increments found (both parameters in comparison to the
control group, (DNA-EnvB/MVA-EnvB i.n immunized without
adjuvants) (Figure 1B). Interestingly, these analyses showed that
co-delivery of both mucosal adjuvants (DNA-IL-12 and CTB)
incremented both measures (%AE and Mean fold increment).
When the specific IFN-c secreting CD8 T-cells found in the
different tissues was evaluated as a whole (Figure 1B), it was
observed that the immunization regime applied in the IL-1250+
CTB group generated the best results in terms of increments
afforded and also in relation to the percentage of adjuvant efficacy
found (100% of the experiments for all the tissues studied).
Incorporation of DNA-IL-12 plus CTB in DNA/MVA
intranasal immunizations also benefits the humoral arm
of the specific immune response
The analysis of the potential antibody enhancement by the
combination of IL-12 and CTB after intranasal immunization was
previously described for HIV-1 gp120, but in a vaccine
formulation in which both the antigen and the cytokine were
administered as recombinant proteins [17]. In that report, it was
found that IL-12 and CTB act synergistically to enhance both
systemic and local mucosal antibody responses to HIV-1
glycoproteins. DNA/MVA immunizations applied in the present
study implied a combination of vaccine vectors which predomi-
nantly targets and maximizes the T-cellular arm of the specific
immune response. Nevertheless, specific Ab targeting was previ-
ously reported after mucosal DNA/MVA immunizations. Thus,
we decided to investigate the specific humoral immune response
found after the different mucosal immunizations applied (Table 1).
After 10 days from the boost immunization, IgG anti-gp120 levels
were evaluated in sera from individual mice of the different
groups. We found that groups which showed significant incre-
ments (p,0.05) in the median IgG absorbance values with respect
to the control group were the IL-1250, IL-1250+CTB, CTB, and
CT groups (Figure S2A). An in depth examination of the specific
IgG subclasses induced, indicated that the presence of CTB during
the immunizations incremented the IgG1/IgG2a ratio (Figure
S2B). Comparison of the anti-gp120 specific IgG1/IgG2a values
between the different groups showed that the higher proportions
were found in those groups which received CTB or CT, therefore
significant increments (p = 0.03) in the median IgG1/IgG2a values
respect to the control group were only found in the groups IL-
12100+CTB, IL-1250+CTB, CTB, and CT.
Afterwards, mucosal specific IgA antibodies were evaluated in
the genital tract (vaginal washings samples) quantifying the specific
IgA levels. Figure S2C shows the median specific IgA values
(referred as IgA fold-increments in relation to pre-immune levels)
obtained in the different groups. In general a high dispersion was
found, however we observed that for certain groups in which the
DNA/MVA immunization was applied with mucosal adjuvants
(CT, IL-1250, IL-1250+CTB and IL-12100+CTB), IgA levels were
above the control group. In the IL-1250+CTB group, specific
vaginal IgA levels were significantly incremented reaching 4.12
fold values (p = 0.0146 vs control group) and variability inside this
group was minor in relation to the others (median 5.767 [IQ 3.073
to 7.223] vs IL-12100+CTB median 11.62 [IQ 1.267 to 22.56]).
Thus these results indicated that improvements of DNA-IL-12
plus CTB nasal co-inoculation during DNA/MVA immunizations
were also detected in the specific systemic and mucosal humoral
response generated.
Nasal co-administration of IL-12 plus CTB improved the
quality of the mucosal specific cellular immune
responses in the genital tract
After the results described above, we decided to evaluate in-
depth the specific mucosal immunogenic profile generated after
immunization in IL-1250+CTB group (details of immunization
scheme in Table 1). Thus, cellular mucosal immune responses
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generated in the genital tract (Figure 2A) and in the genito-rectal
draining lymph nodes (ILNs) (Figure 2B) were studied in
comparison with the response found in the control group with
non adjuvants. As previously shown (Figure 1A) in the ILNs,
significant increments in the quantity of specific IFN-c secreting
cells were found, and importantly specific IL-2 secreting cells were
also incremented (2.6-fold) (p,0.01) (Figure 2B). More relevant
was the finding that specific T-cell responses found at the mucosal
effector site (genital tract) were improved in the group which
received the adjuvants (IL-1250+CTB), as IFN-c secreting cells
were incremented from 147 to 356 SFU/106 cells (p = 0.00164).
The number of IL-2 secreting cells detected at this site was lower
than IFN-c but also tended to be higher in the IL1250+CTB
group. Indeed, it must also be noted that specific IL-2 secreting
cells in the spleen of mice from this group were also significantly
incremented (from 163 SFU/106 cells in the control group to 331
SFU/106 cells in the IL-1250+CTB group, p,0.001, data not
shown). To further analyze the specific cytokine pattern secretion
by the ILNs lymphocytes, supernatants from lymphocyte-cultures
restimulated with the specific Env peptide were analyzed for the
Figure 1. Nasal co-administration of DNA-IL-12 plus CTB cooperate to induce an enhancement effect in the cellular immune
responses against HIV-1 Env antigen during DNA/MVA immunization schemes. Groups of four to six BALB/c mice were inoculated as
described in the immunization schemes (Table 1). (A) Ten days after the booster dose, specific cellular immune responses (IFN-c secreting CD8 T-cells)
against Env were quantified by ELISPOT using pooled cells from spleen, cervical lymph nodes (CLNs) and iliac lymph nodes (ILNs). Bars represent the
average number of specific IFN-c spots forming units (SFU)/106 cells +SD of a representative experiment from 2 to 6 performed. Each determination
was evaluated in duplicate or triplicate and background values from negative control wells were subtracted. Statistical differences between indicated
groups: *p,0.05; **p,0.01; ***p,0.001; by one-way ANOVA test and Bonferroni’s correction post-test. (B) Summarize of the results obtained in all
the experiments performed. Left bars (white) represent the mean fold increments in the magnitude of the specific cellular immune response
compared to the control group. Right bars (grey) represent the percentage of experiments with adjuvant efficacy (%AE); %AE: represents a significant
increase in the specific cellular immune response induced compared to the control group.
doi:10.1371/journal.pone.0107524.g001
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production of Th1/Th2 cytokines, by the CBA kit, and as it can be
appreciated in the right panel of Figure 2B, not only IFN-c levels
but also TNF (Th1) and IL-5 (Th2) cytokines were significantly
elevated in the IL-1250+CTB group.
These results clearly showed the benefits of the nasal co-
inoculation of DNA-IL-12 and CTB in DNA/MVA mucosal
immunization regimes to improve the specific cellular response in
the spleen and also in mucosal HIV target sites as the genital tract
and iliac nodes which drain the genito-rectal mucosa.
Improvements on T-cell response generated by DNA-IL-
12 plus CTB administration during DNA/MVA
immunizations were maintained during the memory
phase of the adaptive response
The results described in the previous section were analyzed after
ten days of the booster MVA dose, indicating that the best
combination to generate adequate anti-Env B responses at both
systemic and mucosal target tissues was DNA-IL-1250 dose plus
CTB in combination with the antigen (DNA-EnvB) at priming,
and CTB plus MVA-EnvB during the booster dose. According to
this, our next aim consisted in evaluating whether the improve-
ments afforded in this group were still present at later times post-
immunization. Thus, the cellular immune response against Env
was analyzed in the different tissues after 30 or 53 days from the
booster immunization dose (Figure 3). Cellular responses evaluat-
ed in the spleen (Figure 3A) indicated that at later times post-
immunization (30 and 53 dpi) mice from the IL-1250+CTB group
showed two to three-fold increments in the number of specific
IFN-c and IL-2 secreting cells respectively. This result indicated
that the increment observed for this group at earlier times (10 dpi,
Figure 1A), was maintained despite the contraction of the
response. Thus, significant differences were still detected com-
pared to the control group during the memory phase, and also, the
pattern found at 30 dpi was maintained at 53 dpi for both CD8 T-
cell specific IFN-c and IL-2 secreting cells. Undoubtedly, an
important finding was that the nasal immunization scheme
selected resulted efficient to produce significant increments in
the memory specific cellular immune responses evaluated in
genito-rectal draining lymph nodes (ILNs) (Figure 3B) and in the
genital tract (Figure 3C). In the ILNs at 30 dpi, increments
detected were similar to those found in the spleen, (2.2 and 1.35-
fold for IFN-c and IL-2 SFU/106 cells respectively), and
afterwards at 53 dpi, the magnitude of the response as well as
increments detected were nearly maintained (3.5-fold in the IFN-c
response). In the genital tract at these times post immunization we
could only evaluate the IFN-c response, as quantities of specific
IL-2 cells were very low, but remarkably in this site, at both 30 and
53 dpi, the IL-1250+CTB group showed nearly 2,5-fold increments
in the proportion of specific IFN-c secreting cells with respect to
the control mice (at 53 dpi p,0.01).
The results of this part of the study demonstrated that the
intranasal DNA/MVA immunization scheme selected (prime:
DNA-EnvB+DNA-IL-1250+CTB/boost: MVA-EnvB+CTB) main-
tained at later times significant increments in the specific IFN-c and
IL-2 T-cell responses against HIV Env antigen, in comparison with
the control group in which neither IL-12 nor CTB were applied.
Mucosal IL-12 plus CTB modulation of the T-cell
functional profile: Influence on the T-cell capacities of
degranulation and specific cytokine pattern production
The importance of T-cell polyfunctionality, defined as those
cells that have multiple effector functions, including the degran-
Figure 2. Nasal co-administration of IL-12 plus CTB improved the quality of the mucosal specific cellular immune responses in the
genital tract. Groups of six BALB/c mice were immunized following the control: (DNA-EnvB/MVA-EnvB: grey bars) and IL-1250+CTB (DNA-EnvB+DNA-
IL-12+CTB/MVA-EnvB+CTB: black bars) immunization schemes described in Table 1. Ten days after the MVA booster dose specific cellular immune
responses against Env peptide were quantified by ELISPOT assay (IFN-c and IL-2 secreting CD8+ T-cells) in (A) genital tract and (B) iliac lymph nodes
(ILNs, left panel). Data are representative of three independent experiments with comparable results. (B, right panel) Iliac lymph-node (ILNs) cells were
stimulated with specific peptide during 72 h and cytokines were measured in culture supernatants using the mouse Th1/Th2 cytokine cytometric
bead array (CBA). Bars represent the average values +SD of duplicate determinations from pooled samples. Background values of negative control
(RPMIc) were subtracted. Responses were considered as positives if they were above the cut-off values (RPMI +3SD). Statistical differences between
groups: **p,0.01; ***p,0.001 by Student’s T test.
doi:10.1371/journal.pone.0107524.g002
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ulation capacity (measured as CD107a/b positive cells) and the
production of cytokines/chemokines has been hardly described. In
the context of HIV infection and HIV vaccination, several studies
have found the association of a specific polyfunctional response as
a marker indicative of T-cell efficacy [31]. Specifically, certain
polyfunctionality capacities as a higher proportion of HIV-specific
cells able to both degranulate and secrete IFN-c were associated
with an improved viral suppression of viral replication during HIV
acute infection [32].
Taking these important facts into account, our next aim was to
analyze the quality of the response generated by DNA-EnvB+
DNA-IL-1250+CTB/MVA-EnvB+CTB in comparison with the
control group. Thus, the ability of the specific CD8 T-cells,
induced after this mucosal immunization, to degranulate and
produce different cytokines (IFN-c, TNF-a and IL-2) was
evaluated by an ICS assay. Figure 4A-C shows the analysis of
T-cell responses in the spleen ten days after immunization. In
concordance with the results described in Figure 1, we found a
significantly higher percentage of specific CD8 T-cells able to
produce IFN-c (p,0.01) or TNF-a (p,0.01), or to degranulate
(CD107a/b+ cells) (p,0.01), in the IL-1250+CTB group in
comparison to the control one (Figure 4A). Then, the proportion
of specific CD8 T-cells exerting one, two or three functions was
analyzed (Figure 4B). In the IL-1250+CTB group, a significantly
higher proportion of specific bi-functional cells was found (in
relation to the total specific cells: 45% in IL-1250+CTB vs 15% in
the control group), implying 0.4% vs 0.077% of total CD8 T-cells
(p = 0.022). Then, when polyfunctionality was analyzed taking into
account the specific combination of functions, we corroborated
that improvements found in the IL-1250+CTB group were
attributed to a higher proportion of tri-functional CD8 T-cells
able to secrete IFN-c+, IL-2+ and TNF-a+ (p,0.001), and to
higher proportions of bi-functional CD8 T-cells that simulta-
neously produce IFN-c and TNF-a (p,0.01) and also to bi-
functional CD8 T-cells able to degranulate and secrete IFN-c
(CD107a/b+ IFN- c+) (p,0,001) (Figure 4C). The same analysis
was done with genital tract cells to characterize the functional
profile of the specific CD8 T-cells present at the mucosal genital
tract site (Figure 4D). The results obtained showed that in the IL-
1250+CTB group, a significantly higher proportion of cells that
produce IFN-c compared to the control group (DNA-EnvB/
MVA-EnvB without adjuvants) was induced (p = 0.038). We also
found that specific CD8 T-cells able to degranulate tended to be
higher in the IL-1250+CTB group, but in none of the two groups
we detected TNF-a production. The polyfunctional evaluation of
these cells is depicted on the right panel. Importantly, bi-functional
cells were only detected in the IL-1250+CTB group (IFN-c+ and
CD107a/b+ cells).
At later times post-immunization (30 and 53 dpi), the Th1/Th2
cytokine pattern secreted in the splenocyte-supernatants was
analyzed after the in vitro restimulation with either the specific
Env peptide (Figure 4E) or the rgp120 protein (Figure 4F). After
Env peptide restimulation the analysis employing the CBA kit,
revealed that higher levels of IL-2, IFN-c and TNF were produced
in the IL-1250+CTB group in consonance with the results found
after ICS at earlier times post-immunization (Figure 4A). After
gp120 restimulation, as expected for a DNA/MVA based
immunization schedule, a marked Th1 pattern was found, which
was significantly incremented (IFN-c, IL-2, TNF) by the co-
administration of DNA-IL-12 + CTB during the prime and the re-
Figure 3. T-cell response improvements afforded by DNA-IL-12
plus CTB administration during DNA/MVA immunizations were
maintained during the memory phase of the adaptive
response. Thirty or 53 days post- immunization, Env specific IFNc
and IL-2 secreting T-cells were evaluated by ELISPOT using pooled cells
from six mice in (A) spleen, (B) iliac lymph nodes (ILNs) and (C) genital
tract for DNA-EnvB/MVA-EnvB control group (grey bars), and DNA-
EnvB+DNA-IL-1250+CTB/MVA-EnvB+CTB group (black bars). Bars repre-
sent the average of spot forming units (SFU)/106 cells +SD for duplicate
or triplicate wells. Background values of negative control wells were
subtracted. Data are representative of three (30 days) and two (53 days)
independent experiments. Statistical differences between groups: *p,
0.05; **p,0.01; ***p,0.001 by Student’s T test.
doi:10.1371/journal.pone.0107524.g003
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inforcing of the MVA boost by the co-delivery of CTB. These last
results indicated that IL-12 plus CTB not only improved the
magnitude of the responses but also benefited the quality of the
cellular responses induced evaluated as T-cell polyfunctionality
and variety of cytokines secreted.
Impact on T-cell quality measured by its proliferative
potential and its ability to recognized cross-reactive
peptides
We also analyzed the specific proliferative potential of the T-cell
response generated, for this we performed CFSE-based prolifer-
ation assays in which experiments were carried out at ten dpi and
also during the memory phase of the adaptive response
(Figure 5A). We found that the percentage of Env-specific
proliferative CD8 T-cells was incremented in the IL-1250+CTB
group. At 10 dpi a tendency to higher percentage of proliferative
cells was detected in the group with adjuvants vs the control group
(2.3% vs 1.75%) but more importantly, the difference between
both groups was much pronounced at later times (30 dpi and 53
dpi), when cells from IL-1250+CTB mice showed an increase in
the specific proliferation capacity in up to four-fold in relation to
that observed in the control group (30 dpi, 0.97% vs 0.21%,
p = 0.012).
An immune response directed against HIV with higher breadth,
having the ability to recognize multiple epitopes and/or different
variants of the targeted peptides, is a desired feature to be hold by
a vaccine formulation. Considering this fact as an important skill
that an immunization schedule must have, we proceeded with the
analysis of the cross-reactivity against a pool of peptides from
gp160 of different HIV subtypes. For this, we performed an
ELISPOT assay using the Env PTE (Potential T-cell Epitopes)
Figure 4. Mucosal IL-12 plus CTB modulates the T-cell capacities of cytotoxicity and specific cytokine pattern production in spleen
and genital tract. Quality of the response was evaluated in pooled samples from six mice immunized as DNA-EnvB/MVA-EnvB (grey bars) and DNA-
EnvB+DNA-IL-1250+CTB/MVA-EnvB+CTB (black bars) groups. (A) Ten days after the MVA boost, the proportion of cytokine secreting (IFN-c, TNF-a and
IL-2) and cytotoxic (CD107a/b) specific CD8+ T-cells against V3 loop were determinated by ICS in splenocytes. (B) Considering the total of specific CD
8+ T-cells, percentages of monofunctional (1fx, white), bifunctional (2fx, grey) and trifunctional (3fx, black) cells are represented. (C) Percentages of
specific CD8 T-cells detailing the function performed. (D) The same analysis performed in (A) and (C) was done for genital tract cells. The percentage
of specific CD8 T-cells able to secrete IFN-c, TNF-a, or with cytotoxicity capacity (CD107a/b+ cells) and polyfunctionality are depicted in the left and
right panel respectively. Bars represent the average +SD for duplicate of pooled cells from six mice. Statistical differences between groups: *p,0.05;
**p,0.01; ***p,0.001 by Student’s T test (E) 53 days after the boost dose, splenocytes from immunized mice were stimulated with V3 loop peptide
during 72 h and cytokines were measured in culture supernatants using the mouse Th1/Th2 cytokine cytometric bead array (CBA). (F) 30 and 53 days
after the MVA boost, splenocytes were stimulated with recombinant Gp-120 protein and cytokines were measured as in (E). Bars represent the
average values +SD of duplicate determinations from pooled samples. Background values of negative control (RPMIc) were subtracted. Responses
were considered as positive if they were above the cut-off values (RPMI +3SD).
doi:10.1371/journal.pone.0107524.g004
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peptide set, in which a total of 480 peptides representing A, B, C
and non-ABC HIV-1 gp160 subtypes were included. In this case,
the peptide set was divided into five pools: Gp1201 (aa 1 to 154)
including the first constant (C) and variable (V) structural domains
of the protein (C1 and V1), Gp1202 (aa 155 to 284) including V2
and C2, Gp1203 (aa 285 to 511) spanning from V3 to C5
inclusive, and finally the peptides that comprise the Gp41 portion
of the protein were divided into two pools: Gp411 (aa 512 to 689)
and Gp412 (aa 690 to 842) (Figure 5D). Results from PTE
ELISPOT assays performed 10 days after the last immunization
dose, showed that a significantly higher total response (of up to six-
fold, p,0.001) against the gp160 PTE peptides (evaluated as the
sum of SFU/106 cells detected against each of the five Env
peptide-pools) was detected in mice which received the adjuvants
(IL-1250+CTB) (Figure 5B left panel). Then, when the response
was studied in a more in-depth analysis taking into account the
responses against the different peptide-pools in which the Gp160
PTE peptides were divided, we verified that the main differences
between both groups were detected in the response directed
against the Gp1201, Gp1203 and Gp412 pools (Figure 5C left
panel).
Data from two independent experiments showed significant
differences against Gp412 pool in both experiments (p,0.01)
whereas responses against Gp1201 and Gp1203 pools resulted
Figure 5. CD8+ T-cell quality measured by its proliferative potential and its ability to recognized cross-reactive peptides. Specific
cellular immune responses were analyzed at 10, 30 or 53 days after the immunization in groups of six BALB/c mice. Pooled splenocytes of DNA-EnvB/
MVA-EnvB (grey bars) and DNA-EnvB+DNA-IL-1250+CTB/MVA-EnvB+CTB (black bars) groups were evaluated. (A) CFSE-labeled cells were stimulated in
vitro during 4 days with the specific V3 loop peptide and then stained with surface antibodies (CD3 and CD8). Proliferating CFSE low CD8 T-cells was
determined by flow cytometry. A representative dot plot is depicted (left panel) and percentage of proliferating cells were analyzed (right panel). (B)
Ten and 53 days after immunization, splenocytes were stimulated with different pools of Env PTE peptides and evaluated by ELISPOT. Bars
represented the accumulated number of IFN-c spot forming units (SFU)/106 cells for the total PTE peptide-pools. (C) Magnitude of the response
against the individual PTE peptide-pools is depicted. (B) and (C): Data are representative of two independent experiments. Bars represent the average
+SD for duplicate samples. Background values were subtracted in each case. Statistical differences between groups: *p,0.05; **p,0.01; ***p,0.001
by Student’s T test. (D) Scheme indicating the gp160 region included in the different PTE peptide pools.
doi:10.1371/journal.pone.0107524.g005
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significantly higher in the IL-1250+CTB group (p,0.001 and p,
0.05 respectively) in 1 out of 2 experiments. More importantly was
the fact that at 53 dpi, during the memory phase of the response,
the pattern of the responses observed at earlier times (Figure 5B)
was conserved. Thus, the total response against the PTE peptide-
pools comprising the whole Gp160 sequence was significantly
higher (three to four-fold higher) in the IL-1250+CTB group vs the
control mice (p,0.01) (Figure 5B right panel). Then, when we
considered the T-cell responses against the different PTE peptides
pools, significant differences were found against the same regions
detected previously at 10 dpi (Gp1201, Gp1203 and Gp412)
(Figure 5C right panel).
These results demonstrated that the co-administration of IL-
1250 plus CTB during the priming and CTB during the booster,
also improved the specific proliferative potential of the CD8 T-cell
response induced. Furthermore, another important advantage was
the fact that this immunization scheme induced T-cells that were
able to recognized heterologous peptides to the antigen expressed
from the vaccine, thus enhancing the breadth of the cellular
response induced.
Improvements in T-cell functional avidity and in vivo T-
cell specific killing
Another feature of the T-cell response that correlated with
effectiveness in their effector functions is the cellular avidity for the
antigen. Regarding HIV infection, recent studies demonstrated
that individuals with the capacity to control the infection harbor
CD4 T-cells with the intrinsic ability to recognize minimal
amounts of Gag antigen [33], and also that the presence of high-
avidity Gag-specific and HLA-B restricted CTL response corre-
lated with viral suppression in vivo [34]. Taking into account this
background information, we analyzed the T-cell avidity induced
against the Env V3 peptide after applying the immunization
scheme of the IL-1250+CTB group. For this, we performed
ELISPOT assays at different peptide concentrations, making serial
dilutions. In these experiments, the T-cell avidity power is reflected
by the capacity of T-cells to recognize its specific peptide-ligand at
low concentrations, and it is expressed as the peptide concentra-
tion that is required to detect 50% of the maximal specific T-cell
response: SD50 (sensitizing dose of peptides required to yield 50%
of maximal T-cell triggering IFN-c production). Interestingly, T-
cells from the group in which IL-12 and CTB were included,
showed a significantly higher avidity against the Env V3 peptide,
thus the SD50 resulted three times lower for the IL-1250+CTB
group compared to the control group (1.18 vs 3.48 ng/ml
respectively p = 0.0136) indicating a superior capacity to detect
lower quantities of the specific antigen (Figure 6A). More
important was the fact that we could demonstrate that the
improvements in the T-cell avidity properties observed in the
group with adjuvants were still present after 30 days of the
immunization schedule, and at this time differences between both
groups were enhanced. Figure 6B depicts the curves for the
percentages of maximal IFN-c secreting cells vs the concentration
of the specific peptide-ligand, found at 30 dpi, and it can be seen
that whereas in the IL-1250+CTB group the SD50 value was nearly
maintained in relation to that observed at 10 dpi (Figure 6A)
(1.95 ng/ml (30 dpi) vs 1.18 ng/ml (10 dpi)) (p.0.05), the SD50
value for the control group was significantly incremented
(10.56 ng/ml (30 dpi) vs 3.48 ng/ml (10 dpi)) (p = 0.026).
Therefore, during the memory phase of the response the difference
between the T-cell affinity capacities for both mice groups was
increased, being the SD50 value for the IL-1250+CTB group 5.4
times minor than that observed in the control one (p = 0.0035).
Finally, we considered relevant to perform an assay whereby we
could evaluate in vivo the quality of the T-cell response induced.
For this purpose, we selected an assay to measure the level of
specific killing capacity of the CD8 T-cells evaluated in vivo,
considering a solid way to evaluate the quality of the response, and
to corroborate if differences evaluated by in vitro functional assays
(as IFN-c secretion by ELISPOT assay, ICS or avidity curves) are
readily reproduced by an in vivo functional assay. The steps
applied in the development of this assay are described in detail in
the methods section. Briefly, ten days after immunization, mice
from the different groups (control, IL-1250+CTB and naı¨ve) were
intravenously injected with CFSE labeled control and Env
peptide-pulsed target spleen cells. After 4 h and 16 h animals
were sacrificed and specific lysis was analyzed by flow cytometry.
Figure 6C left upper panel shows representative data of CFSE
histograms observed in the naı¨ve mice, in which the two peaks of
the histograms corresponding to CFSEhigh (peptide-pulsed) and
CFSElow (un-pulsed) target-cell populations have similar sizes,
indicating that in naı¨ve mice after 4 h or 16 h post inoculation
similar quantities of both target-cell populations were recovered
(Figure 6C, left panel). On the contrary, in mice from immunized
groups (middle and inferior panels) the histograms corresponding
to CFSEhigh (peptide-pulsed) cells were diminished in relation to
the CFSE low histograms, being this difference more pronounced
for mice of the DNAEnvB+DNAIL-1250+CTB/MVA-EnvB+
CTB immunized group (IL-1250 +CTB). Percentage of specific
in vivo cytolisis was analyzed at 10 dpi and 30 dpi. After 10 days
cytotoxicity was evaluated at 4 h and also 16 h post-transfusion
(pt) of the CFSE dyed cells. As it can be appreciated in the middle
panel of Figure 6C, in the IL-1250+CTB group the percentage of
cytoxicity levels detected 4 h and 16 h pt of cells was nearly 3.9
and 3.2 times higher than the percentage observed in the control
group. At 4 h pt although higher values of percentage of
cytotoxicity were detected in the group with adjuvants, differences
between both groups did not reach statistical significance. Later at
the time point of 16 h pt, median values of cytotoxic activity found
in IL-1250+CTB mice group were significantly higher compared to
those detected in the control mice (median values of 53.03% vs
16.37% p = 0.0043). When the in vivo killing assay was performed
during the memory phase of the adaptive T-cell response
(Figure 6C right panel) we found that in vivo cytotoxic activity
was still detected, and the comparison between both mice groups
showed median cytotoxicity values of 3.51% (control) vs 17.51%
(IL-1250+CTB) (p = 0.057).
These last experiments demonstrated a direct correlation
between CD8 T-cell effector functions exerted in vivo and specific
T-cells assays previously analyzed in vitro.
Memory T-cell subpopulations induced after DNA/MVA
immunization schemes showed a distinctive phenotype
in which IL-12+CTB co-administration generated an
enhancement of T-cells from earlier stages of
differentiation
Finally, we proceeded to characterize more in depth the
phenotypic pattern of the T-cell memory response induced in
order to define if the improvements achieved after the co-
administration of IL-12 and CTB were accompanied by differ-
ences in the specific T-cell memory sub-populations generated. To
do this, DNAEnvB+/MVA-EnvB and IL-1250+CTB groups were
immunized as in previous experiments, and 30 days later T-cell
specific responses were analyzed by ICS and by their specific
proliferative capacity with CFSE-based assays. By the co-staining
of CD8 T-cells with surface markers, T-cells that responded to the
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antigen (and are therefore memory cells) were grouped into four
categories: ‘‘early memory or T stem cells memory’’ (TSCM:
CD44- CD62L+), central memory (CM: CD44+ CD62L+),
effector memory (EM: CD44+ CD62L-), and terminal effector
cells (TE: CD44- CD62L-). In these experiments, splenocytes were
restimulated during 4 days with the specific peptide or with RPMI
only, in order to evaluate the level of specific proliferation by the
dilution of the CFSE staining. Then, the distribution of the CD8
T-cell subpopulations was analyzed by flow-cytometer inside the
cells that showed proliferation against the specific stimuli. It can be
seen that in the IL-1250+CTB group the percentage of CD8 T-
cells that proliferated against the specific peptide was significantly
incremented (nearly four-fold) with respect to the values observed
in the DNA-EnvB/MVA-EnvB control group immunized without
adjuvants (Figure 7A). When the distribution of specific memory
T-cell populations was compared between both groups, it was
notably revealed that mice immunized with the IL-1250+CTB
scheme showed significantly higher proportions of CD8 specific
cells with CM (0.1455% vs 0.013%; p,0.02) and with TSCM
phenotypes (1.14% vs 0.098%; p,0.001) (Figure 7A). Figure 7B
illustrates the distribution of the antigen-specific cells among the
different maturation stages for the two mice groups. It can be
clearly seen that after the IL-12+CTB immunization the fraction
of cells with an effector phenotype (EM plus TE) was significantly
reduced (69% in control vs 18% in IL-12+CTB). Thus, the T-cell
phenotypes that resulted significantly incremented after the DNA-
IL-12 plus CTB co-administration were associated with T cells
from earlier stages of differentiation (TCM and TSCM-like cells).
Discussion
In this study we analyzed the feasibility and efficacy of the
incorporation of DNA-IL-12 and CTB as mucosal adjuvants
during the administration of DNA/MVA vectors by intranasal
route, employing vectors expressing the gp160 HIV-1 antigen as a
model. The results described show that DNA-IL-12 plus CTB can
be effectively employed acting as mucosal adjuvants during DNA
prime/MVA boost vaccine doses applied by intranasal route. The
importance of the results presented here relies in two original
relevant findings: a) the capacity of IL-12 and CTB when
administered by intranasal route to cooperate in their adjuvant
action enhancing both the magnitude and quality of the cellular
immune responses induced at systemic tissues (in the spleen) and
mucosal sites (CLNs, ILNs and genital tract), b) the description of a
new mucosal adjuvant-combination, with potential clinical appli-
cation, that resulted extremely effective to improve the quality and
magnitude of the cellular responses generated by a DNA/MVA
mucosal immunization.
The relevance of expanding the knowledge about strategies
related to mucosal vaccines is a worldwide concern, as most
pathogens access the body through the mucosal membranes and
so effective vaccines with the ability to protect at these sites are
needed. However, after the oral polio vaccine few new mucosal
vaccines have been launched afterwards. One of the reasons for
this is the absence of safe and effective mucosal adjuvants [8].
Regarding HIV vaccines, mucosal surfaces are not targeted by
most of the current vaccines on clinical trials, except for isolated
cases [35].
The delivery of HIV antigens by the DNA prime/MVA boost
strategy has been largely probed and now it is being employed in
diverse ongoing clinical trials. The application of these antiHIV/
SIV vaccine regimes by intranasal route were previously
performed in murine and macaque models [5,7]. Significantly in
one of these studies it was demonstrated that nasal DNA/MVA
Figure 6. Study of T-cell functional avidity and in vivo T-cell
specific killing activity. Pooled splenocytes from control and IL-
1250+CTB groups (three to six mice/group), were analyzed for functional
avidity of the V3- loop specific T-cells at (A) 10 and (B) 30 days after
immunization, by ELISPOT using serial dilutions of the peptide from 20
to 0.00002 mg/ml for triplicate wells. Data represents the average
percentage of the maximal response. SD50: sensitizing dose of peptide
required to yield 50% of maximal T-cell triggering IFN-c production. (C)
In vivo cytotoxicity was analyzed adoptive transfer of control CFSElow
and Env-peptide pulsed CFSEhigh dye cells. At 10 and 30 days after
immunization, individual spleens of mice from naı¨ve (I), DNA-EnvB/
MVA-EnvB (II) and DNA-EnvB+DNA-IL-1250+CTB/MVA-EnvB+CTB (III)
groups were analyzed at the indicated times after adoptive transfer.
A representative histogram is depicted in the left panel. Dots represent
each analyzed mice. Lines represent median Statistical differences
between groups: *p,0.05; **p,0.01 by Mann-Whitney test.
doi:10.1371/journal.pone.0107524.g006
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SIV vaccination provides more significant protection from
progression to AIDS than a similar intramuscular vaccination [7].
In the designing of mucosal vaccine strategies, the selection of
an appropriate adjuvant is crucial in order to generate an effective
mucosal immunization. In the present study, we hypothesized that
intranasal DNA/MVA immunization may be improved by the
inclusion of IL-12 and CTB as adjuvants. The benefits of the co-
administration of these molecules by intranasal route have been
previously explored, but with a different immunization strategy in
which a recombinant protein was administered, and only it was
analyzed the capacity to improve the humoral arm of the response
[17].
Previous studies have demonstrated that CTB can act as an
efficient mucosal adjuvant to enhance both mucosal and systemic
antibody responses [36]. Additionally, CTB was shown to be
efficient at promoting MHC class I cross-presentation of
exogenous antigens by murine dendritic cells, these features were
demonstrated with antigens conjugated to or simply mixed with
CTB [37]. However, a novel finding of the present study is to
demonstrate the intranasal mucosal adjuvant effect of CTB to
enhance CD8 T-cell responses at a distal mucosal site as the
genital tract. In a previous study in which it was also shown a CTB
T-cell enhancing effect at the genital tract after its administration
from a distal mucosal route (sublingual delivery), the CTB effect
alone cannot be correctly evaluated because even when it was
coupled to the Pol peptide antigen, the complete cholera toxin
(CT) was also co-administered during immunizations [38]. A
similar fact occurred in another work in which a fusion protein
consisting of the cholera toxin B subunit and a 36-residue peptide
of the conserved membrane proximal ectodomain of gp41 (CTB-
MPR649–684) was analyzed using different mucosal routes in
relation to its potential to induce either systemic or mucosal anti-
MPR649–684 antibodies. In that study, various immunization
regimens were examined but mucosal delivery of CTB-MPR649–
684 was always accompanied with CT [39].
In relation to IL-12, its administration by mucosal routes was
previously described to be effective in the enhancement of cellular
immune responses at both systemic and mucosal sites [40,41].
However, the interaction effects of IL-12 plus CTB administered
by intranasal route has not been analyzed in depth. Plasmid
encoded IL-12 has proven to be a promising candidate adjuvant,
enhancing cellular immune responses when applied during DNA
prime-viral vector boost vaccine regimens against HIV or SIV
antigens [12,28,42]. Interestingly, in a recent preclinical macaque
experimental design it was demonstrated that systemic immuni-
zation with DNA-IL-12 in a DNAprime and recombinant Ad
boost vaccination generated an enhanced control against a
pathogenic low-dose intra-rectal SIVmac239 challenge [42].
Here we demonstrate that by the co-delivery of the non-toxic
CTB mucosal adjuvant with DNA-IL-12 during the intranasal
DNA/MVA vaccine regimen, an enhancement of the magnitude
of the specific CD8 T-cell responses is generated not only in
systemic tissues (spleen) but also in mucosal lymph nodes proximal
to the immunization site (CLNs) and in those draining genito-
rectal tissues (ILNs). In the spleen we observed that when IL-12
was administered alone generated a two-fold increment, but when
CTB was co-administrated with the DNAprime and MVAboost
doses, a co-operative enhancement was detected of up to seven-
fold increments (IL-1250 dose) in the magnitude of the response
compared to that detected in the control group (mean of 1257 vs
185 IFN-c SFU/106 cells). Undoubtedly, a significant finding was
to demonstrate an improvement of the specific cellular response at
the genital tract, which functions as a crucial mucosal effector site
acting as a barrier against the virus. Moreover, the improvements
detected during the acute phase of the immune response were
maintained during the memory phase, where we analyzed the
specific immune response induced in the spleen, ILN and genital
tract up to 53 days from the last immunization.
At early times post-immunization we also evaluated levels of
anti-Env specific antibodies generated. Thus, although DNA/
MVA immunizations applied in the present study implied a
combination of vaccine vectors which predominantly targets and
maximizes the T-cellular arm of the specific immune response,
results depicted in Figure S2 indicated that improvements of IL-12
plus CTB nasal co-inoculation were also detected in the specific
systemic and mucosal humoral response generated.
Evidences indicate that the induction of specific CD8 T-cells at
the mucosal portal of entry of the virus is crucial to slow down the
initial HIV replication [43], however from the multiple mucosal
HIV vaccine studies performed until now only a minority of them
analyzed specific cellular responses directly at the mucosal effector
site of the genital tract. As an example, in an interesting paper
Figure 7. Characterization of specific memory T cell subpop-
ulations induced. Thirty days after immunization, pooled-splenocytes
of six BALB/c mice were CFSE- labeled and stimulated with V3-peptide
during 4 days. Then, cells were stained with surface marker (CD8, CD44
and CD62L) and analyzed by flow cytometer. CD8 T-cells with specific
proliferative capacity (evaluated by the CFSE dilution assay) were
classified in four memory subpopulations. (A) Bars represent the
percentage of specific CD8 T-cell with a phenotype compatible with: T
stem cells memory (TSCM; CD44L-CD62L+), T central memory (TCM;
CD44+ CD62L+), T effector memory (TEM; CD44+ CD62L-) and T terminal
effector (TTEM; CD44- CD62L-). (B) Pie charts show the percentage of
specific CD8 T-cells expressing the indicated phenotype. Statistical
differences between groups are indicated: *p,0.05; ***p,0.001 by
Student’s T test.
doi:10.1371/journal.pone.0107524.g007
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published last year the authors described an original mucosal
HIV-1 vaccine strategy based on IL-13Ra2, where the strategy
demonstrated to induce CD8 T-cell mucosal enhancements in
diverse functions. However, this effect was only analyzed in
mucosal draining lymph nodes as the ILNs and PPs, and as
mucosal effector site they only evaluate responses at the lung [44].
Analysis of the modulation of the T-cell functional profile
showed that one of the improvements detected was that the
specific T-cell responses generated showed a higher polyfunction-
ality, with capacity to secrete a broader spectrum of cytokines
(Figure 2–4). Remarkably, genital tract CD8 T-cells were also
modulated after the intranasal DNA/MVA IL-12+CTB scheme,
in the sense that a higher proportion of cells able to produce IFN-c
and CD107a/b+ and of IFN-c/CD107a/b bi-functional cells
were found (Figure 4D).
We have recently published a study in which we analyzed the
impact of the incorporation of GM-CSF and IL-12 during DNA/
MVA systemic immunizations against the HIV-1 Nef antigen. The
results obtained indicated that the incorporation of DNA-IL-12 in
DNA/MVA vaccination schemes produced the best results in
terms of improvements of T-cell response key properties such as
breadth, cross-reactivity and quality (avidity and pattern of
cytokines secreted) [28]. In the present study, similar effects were
found when IL-12 was co-inoculated with CTB by intranasal
route, thus in addition to its improvements with respect to pattern
of cytokines secreted and polyfunctionality, we also found a higher
specific proliferative level and perhaps more relevant was the
finding of a stronger CD8 T-cell avidity (Figure 5A and
Figure 6A). T-cells with high functional avidity respond to very
low antigen doses, in relation to the potential impact of mucosal
vaccinations on T-cell avidity, previous studies indicated the
superiority of a mucosal (intranasal) poxvirus-based immunization
in relation to a systemic (i.m) one to generate higher avidity CTL
responses [45]. Here, although mucosal vs systemic immunizations
were not compared, we could demonstrate the capacity of DNA-
IL-12 in conjuction with CTB to augment the functional avidity of
the CD8 T-cell response induced after its intranasal delivery in
DNA/MVA immunizations. Remarkably, improvements in T-cell
avidity during the memory phase indicated that the SD50 value for
the IL-1250+CTB group was 5.4 times lower than that observed in
the control (differences between both groups were significantly
different (p = 0,0035) (Figure 6B). In relation to the influence that
may have the application of cytokines or adjuvants during
immunization on the avidity of the specific T-cells clones that
are induced, earlier studies have described that IL-12 can promote
an enhanced synapse formation between APCs and T-cells,
leading to the recognition of weak peptides against which T-cells
would be normally unresponsive [46], or that the generation of
high avidity effector CTLs is IL-12 dependent [46,47]. With
respect to CTB and its effects on T-cell avidity there are no reports
in which this topic has been studied until now.
Another improvement of the IL-12 plus CTB in DNA/MVA
nasal immunizations that we could verify along this study was that
the response induced showed a higher breadth evidenced by a
higher cross-reactivity against Env peptides of different subtypes.
Undoubtedly, the induction of a cellular immune response of high
breadth able to recognize Env proteins from different HIV
subtypes is a desired characteristic for an HIV vaccine. Even
more, we had recently described a similar IL-12 improvement for
Nef antigens [28].
Finally we performed an in vivo CTL assay in order to do a
more profound analysis of the CTLs capabilities of the immune
response generated [30], the disadvantages that perhaps in vitro
and ex vivo analysis may have is that they are less informative than
in vivo assays, since they do not take into account the complexity
of the microenvironment where the immune response occurs, and
therefore do not always reproduce what occurs in vivo. Thus,
considering these facts our results demonstrating the superior in
vivo specific cytotoxicity in mice from the IL-1250+CTB group,
contribute to do a more comprehensive analysis highlighting the
relevance of the innovative mucosal DNA/MVA immunization
scheme presented in this work. An important point to denote is
that the level of specific cytolytic capacity of CD8 T-cells evaluated
in vivo, can be considered in a certain manner an indirect measure
of the potential protective capacity of the CD8 T-cell immunity
generated. This concept was previously demonstrated in the
previously published work of Zhongxia Li et.al, [48], in which the
authors demonstrated a direct correlation between high levels of in
vivo cytolytic activity against Gag-peptide-labeled target cells and
the protection capacity against a rVACV-gag virus. But as in the
present study we have applied a rMVA boost in the immunization
scheme, the anti-vaccinia virus immunity generated preclude the
use of the useful rVACV challenge model. Another notion that is
important to take into account is that from the different T-cell
effector functions, the cytolitic activity of CTLs play a prepon-
derant role during SIV/HIV pathogenesis. This concept is
supported by biologically-directed models that indicated a
cytolytic clearance of HIV/SIV infected cells as the main
protective mechanism for CTLs [49].
Memory T cells have been typically divided into two main
subsets based on the expression of the lymph node homing
molecules CD62L and CCR7 [50]. Central memory T cells
(TCM) express high levels of CD62L and CCR7, whereas effector
memory T cells (TEM) express low levels of CD62L and CCR7.
However, recent studies demonstrated the existence of a new
population of memory T cells designated T memory stem-like cells
(TSCM), this T-cell population was first described in mice [51,52]
and more recently a human memory T-cell subset with stem cell–
like properties was also identified [53]. This new T-cell population:
TSCM have a phenotype similar to those of naı¨ve T-cells
(CD44low CD62Lhigh in mice or CD45RO2CD62L+ in
humans), but they differ from naı¨ve cells in different characteristics
being its vigorous proliferative potential upon restimulation with
its specific antigenic peptide, one of the most distinctive [53,54].
When the distribution of specific memory T-cell populations was
compared between both DNA/MVA groups, it was notably
revealed that mice immunized with the IL-1250+CTB scheme
showed significantly higher proportions of CD8 specific T-cells
with a central memory phenotype (TCM) (CD44+ CD62L+)
(0.1455% vs 0.013%; p,0.02) and with a phenotype compatible
with stem cells-like memory T cells (TSCM) (CD44low
CD62Lhigh) (1.14% vs 0.098%; p,0.01) (Figure 7A). Thus, T-
cell phenotypes that resulted significantly incremented after the
DNA-IL-12 plus CTB co-administration were associated with T-
cells from earlier stages of differentiation (TSCM and TCM). A
similar particular pattern of T-cell memory phenotype distribution
as the one found in the present work was already reported for T-
cell memory responses in vaccinees after VACV immunizations
[55] and also in subjects immunized with other vaccines [31].
Freel and co-workers examined the relationship between CD8 T-
cell phenotype and HIV antiviral activity and found that in
general vaccinees (with Ad vectors) have HIV-1 specific cells of an
earlier differentiation stage (including a high proportion of the
phenotype early-memory or ‘‘naı¨ve-like’’) than controllers, while
chronic infected patients have the most-differentiated cells [31]. In
relation to previous studies performed in mice in which T-cell
memory subpopulations against vaccine antigens were studied, it is
striking that in a study published some years ago, it is described
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that after vaccination of mice with Mycobacterium bovis BCG, the
cells expressing a ‘‘resting/naı¨ve-like’’ phenotype (CD44low
CD62Lhigh) similar to that found in the present work, were
capable of protecting the recipients from a virulent challenge
infection [56] . Thus, the finding in the present study in relation to
the capacity of IL-12 plus CTB during DNA/MVA intranasal
immunizations to augment the proportion of specific T cells with a
TSCM-like phenotype is of great importance in the context of
vaccine designs, as the recent identification of a human stem cell-
like memory T-cell population with increased proliferative
capacity and superior protective antitumor responses it was
considered of direct relevance to the design of vaccines and T-
cell therapies [53].
Collectively, our results demonstrate for the first time that
intranasal DNA/MVA immunization schemes can be effectively
improved by the co-delivery of DNA-IL-12 plus CTB, inducing
elevated HIV-specific CD8 responses at systemic places and more
importantly at mucosal sites such as genital tract tissues and ILNs.
To denote, these enhanced CTL responses were of superior
quality showing higher avidity, polyfunctionality and a broader
cytokine profile. Furthermore, by an in vivo CTL killing assay we
could demonstrate the higher specific CD8 T-cell performance
after the IL-12+CTB immunization. Remarkably, the improve-
ments observed were maintained during the memory phase of the
adaptive response where we found higher proportions of the
specific memory T-cell subpopulations: TCM and TSCM after IL-
12 plus CTB nasal co-administration.
Supporting Information
Figure S1 Evaluation of DNA-IL-12 adjuvant effect after
intranasal immunization. Groups of four BALB/c mice were
intranasally inoculated as described in the immunization schemes
depicted at day zero all mice were DNA primed with the specified
DNA vectors described for each group 14 days later all groups
were boosted with MVA-EnvB (107 PFU/dose) (A). Ten days after
the booster dose, specific cellular immune responses (IFN-c
secreting CD8 T-cells) against Env were quantified by ELISPOT
using pooled cells from spleen (B). **: Statistical differences
between groups (p,0.01). Differences respect to the control group
by one-way ANOVA with Bonferroni’s correction post-test.
(TIF)
Figure S2 Specific humoral immune response against gp-120 in
mice immunized with mucosal adjuvants. Ten days after the MVA
boost, antibody levels against gp-120 were quantified by ELISA in
sera (A and B) andvaginal washing (C) samples from immunized
mice. (A) specific IgG absorbances, dotted line represents cutt-off
for positive responses (B) IgG1/IgG2a absorbance ratios. In A and
B, each point represents the mean absorbance values of duplicate
determinations of individual sera from four mice per group diluted
1:50. (C) HIV-1 gp120 specific IgA levels were quantified in
vaginal washings of pooled samples from 4 to 6 mice per group
diluted 1:5. Data represent the mean fold increments in the
absorbance values of pooled vaginal washings samples of the
different experiments, respect to those values detected in pre-
immune mice samples. Cut off to consider positive samples were
values $ to mean values found in naı¨ve samples plus 3SD. *:
Statistical differences between groups (p,0.05). NS: Non signif-
icant differences respect to the control group by Mann-Whitney
test.
(TIF)
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